SEC Tracker
Get the app
QURE · XBRL financial data

uniQure financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (QURE's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
Revenue———————2———4
Revenue from contracts with customers———————2———4
Cost of goods and services sold——year only000year only0100*0
Research and development466543*41343139*36353435*29
Selling, general and administrative211817*14161211*11141922*20
Operating income (loss)(65)(82)(62)*(54)(44)(40)(46)*(39)(44)(51)(51)*(46)
Interest income377*7654*4446*5
Interest expense71516*16161715*15161715*14
Other income (expense)—————————(7)18*4
Income tax expense (benefit)0(0)3*11(0)1*009(4)*0
Net income (loss)——year only—(56)(44)(73)*(44)(38)(81)(37)*(54)
Earnings per share, basic USD per share(1.44)(1.88)—(1.36)(1.16)(0.91)—(0.82)(0.69)(1.38)(0.58)*(0.85)
Earnings per share, diluted USD per share(1.44)(1.88)—(1.36)(1.16)(0.91)—(0.82)(0.69)(1.38)(0.58)*(0.85)
Weighted average shares, basic millions of shares484848*48494949*53555963*63
Weighted average shares, diluted millions of shares484848*48494949*53555963*63

Balance sheet

CSV

Fiscal quarters (QURE's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
Cash and cash equivalents51422924124328825215921725459780140
Marketable securities11542937731323718420919212397543447
Accounts receivable——————————64
Inventory1016128————————
Total current assets757694652596592464390435409716656616
Property and equipment, net494647452626201817151412
Right-of-use asset313029281515141314131312
Goodwill262526262324222325252525
Total assets943872832770731646557605585888825779
Accounts payable967545756654
Accrued liabilities242831232632292731524143
Total current liabilities6869746380714036411016359
Long-term debt10110110210210351515252525050
Lease liability, non-current302928271212111111101010
Total liabilities589603624623634590563572589660626629
Accumulated deficit(728)(817)(890)(956)(1,012)(1,057)(1,130)(1,174)(1,211)(1,292)(1,329)(1,382)
Total stockholders' equity3532692081479756(7)34(4)229199149
Total liabilities and equity943872832770731646557605585888825779
Common shares outstanding (cover page) millions of shares484848494949545555626363

Cash flows

CSV

Fiscal quarters (QURE's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
Net income (loss)——year only—(56)(44)(73)*(44)(38)(81)(37)*(54)
Stock-based compensation9*11*7*77*3*5*45*4*5*5
Net cash from operating activities(57)*39*(50)*(61)(33)*(37)*(53)*(44)(40)*(16)*(78)*(38)
Purchases of property and equipment1*2*2*21*0*0*00*(0)*0*0
Net cash from investing activities46*(314)*60*6478*48*(27)*2073*27*(441)*99
Repayments of long-term debt——————0*—————
Net cash from financing activities370*(8)*0*——(53)*(7)*810*332*2*1
Net change in cash360*(284)*12*245*(38)*(93)*5837*343*(517)*60

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
uniQure985.2(48)*70.1M2.6 quarters 10-QSep 30, 2026
Phibro Animal Health61397*24*not reported— 10-KJun 30, 2026
Pacira BioSciences20619257*39.9M— 10-QJun 30, 2026
Cogent Biosciences181not reported(77)*173.5M10.3 quarters 10-QJun 30, 2026
Syndax Pharmaceuticals13683(27)*not reported11.9 quarters 10-QSep 30, 2026
Immunome2180(62)*113.6M8.4 quarters 10-QJun 30, 2026
Nurix Therapeutics720673616*109.2M— 10-QAug 31, 2026
Niagen Bioscience67302.8*79.1M— 10-QJun 30, 2026
Anavex Life Sciences118not reported(9.1)*92.7M13.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.